Lipocalin fusion partners

US10156559B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10156559-B2
Application numberUS-201314651175-A
CountryUS
Kind codeB2
Filing dateDec 10, 2013
Priority dateDec 10, 2012
Publication dateDec 18, 2018
Grant dateDec 18, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for producing a fusion protein, the method comprising: expressing, in a cell, a fusion protein, the fusion protein comprising: a knotted-peptide selected from PMP-D2, potato carboxypeptidase inhibitor, huwentoxin, imperatoxin, epiregulin, midkine, bubble protein and conotoxin CIVC; and a siderocalin protein selected from human siderocalin, murine siderocalin, chicken Ex-FABP, and quail Q83, thereby producing the fusion protein. 2. The method of claim 1 , further comprising separating the knotted-peptide from the siderocalin protein. 3. The method of claim 2 , wherein the fusion protein further comprises a cleavage site. 4. The method of claim 3 , wherein the cleavage site is a furin cleavage site, a trypsin cleavage site, or a TEV cleavage site. 5. The method of claim 3 , wherein the separating of the knotted-peptide from the siderocalin protein results from cleavage at the cleavage site in the fusion protein. 6. The method of claim 2 , wherein the separating of the knotted-peptide from the siderocalin protein occurs following secretion of the fusion protein from the cell. 7. The method of claim 6 , wherein the cell is a mammalian cell. 8. The method of claim 1 , wherein the fusion protein comprises the following construct: IgK starter sequence-signal sequence-sFLAG-HIS6 (SEQ ID NO: 93)-siderocalin protein-TEV cleavage site-knotted peptide. 9. A composition comprising a fusion protein, the fusion protein comprising: a knotted-peptide selected from PMP-D2, potato carboxypeptidase inhibitor, huwentoxin, imperatoxin, epiregulin, midkine, bubble protein and conotoxin CIVC; and a siderocalin protein selected from human siderocalin, murine siderocalin, chicken Ex-FABP, and quail Q83. 10. The composition of claim 9 , wherein the fusion protein further comprises at least one of an IgK starter sequence, a sFLAG, a HIS6(SEQ ID NO: 93), or a TEV cleavage site. 11. The composition of claim 9 , wherein the fusion protein is generated by direct fusion of the knotted-peptide to the siderocalin protein. 12. The composition of claim 9 , further comprising a linker sequence between the knotted-peptide peptide and the siderocalin protein. 13. The method of claim 1 , further comprising loading the siderocalin protein with a ligand. 14. The method of claim 13 , wherein the ligand comprises a chemotherapeutic or radioactive agent. 15. The composition of claim 1 , further comprising a cleavage site between the knotted-peptide and the siderocalin protein. 16. The composition of claim 15 , wherein the cleavage site is a furin cleavage site, a trypsin cleavage site, or a TEV cleavage site. 17. The composition of claim 9 , wherein the siderocalin protein is loaded with a ligand. 18. The composition of claim 17 , wherein the ligand comprises a chemotherapeutic or radioactive agent. 19. The method of claim 1 , wherein the siderocalin protein is human siderocalin having a C87S mutation. 20. The method of claim 1 , wherein the siderocalin protein is human siderocalin having a C87S mutation, an 18C mutation and a N39C mutation. 21. The composition of claim 9 , wherein the siderocalin protein is human siderocalin having a C87S mutation. 22. The composition of claim 9 , wherein the siderocalin protein is human siderocalin having a C87S mutation, an 18C mutation and a N39C mutation.

Assignees

Inventors

Classifications

  • Immunomodulators · CPC title

  • Drugs for disorders of the cardiovascular system · CPC title

  • Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

  • Antineoplastic agents · CPC title

  • Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10156559B2 cover?
Methods and systems for producing fusion proteins and peptides are disclosed. Fusion proteins and peptides created using the methods are also provided. Also provided are methods of using the fusion proteins and peptides produced according to the present disclosure.
Who is the assignee on this patent?
Hutchinson Fred Cancer Res
What technology area does this patent fall under?
Primary CPC classification G01N33/5008. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).